Lung Cancer Diagnosis Gets an AI Boost with Body Vision’s Latest Funding

Body Vision Medical, a company that uses artificial intelligence to improve real-time imaging during lung cancer procedures, announced it has closed a new round of funding. The Waltham, Massachusetts-based firm did not disclose the amount raised, the round’s structure, or participating investors. The capital comes as the company seeks to broaden adoption of its LungVision platform, which turns a standard 2D C-arm into a 3D navigation system for bronchoscopic biopsy and therapy delivery. LungVision’s core innovation is AI Tomo, a proprietary algorithm that corrects for CT-to-body divergence—the shift in a lung lesion’s position between a preoperative CT scan and the patient’s body during the procedure. That divergence has historically capped diagnostic yields from bronchoscopy at around 70%. Body Vision claims its technology pushes yields toward 95% by providing real-time, tool-in-lesion confirmation. The system also generates better image quality than dedicated 3D C-arms at one-fifth the radiation dose per spin, according to the company. Clinicians at hospitals including Monmouth Medical Center and Italy’s Policlinico Sant’Orsola-Malpighi have adopted the system. In testimonials on the company’s website, physicians describe the ability to biopsy sub-centimeter nodules that were previously unreachable via endoscopic methods. The new funding arrives as demand grows for minimally invasive lung cancer diagnostics. Lung cancer remains the deadliest cancer globally, and early, accurate tissue sampling is critical to treatment planning. Body Vision’s approach competes with robotic bronchoscopy platforms and cone-beam CT systems, but it positions itself as a more economical option that lowers total cost of ownership for hospitals. The company did not specify how it will deploy the fresh capital. However, its website highlights a goal of making cutting-edge lung interventions more accessible worldwide, suggesting sales expansion, regulatory approvals, or product enhancements could be on the horizon.